AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
